Azenta reports FY26 results and projects 3‑5% organic growth with margin expansion in FY27
Azenta Life Sciences posted full‑year 2026 revenue of $622 million and an adjusted EBITDA margin of 9.4%, with fourth‑quarter earnings of $0.28 per share on $167 million of revenue. Management said organic revenue grew 2% in FY26 and guided to 3‑5% organic growth for fiscal 2027, along with 200‑250 basis points of adjusted margin expansion. The company highlighted double‑digit growth in its Sample Repository Services and Consumables & Instruments segments and announced strategic moves in gene‑synthesis to support the outlook.
Why it matters
The company’s guidance suggests higher profitability and modest top‑line growth, which could support a continued share‑price rally noted after the earnings release. Investors will watch whether the projected margin expansion materialises given the announced cost‑saving initiatives.
Key facts
- 1Full‑year 2026 revenue was $622 million. investing.com
- 2Adjusted EBITDA margin for FY26 was 9.4%. investing.com
- 3Q4 2026 adjusted earnings were $0.28 per share on revenue of $167 million. investing.com
- 4Organic revenue grew 2% in FY26. finance.yahoo.com
- 5Azenta guided to 3‑5% organic revenue growth in FY27. tradingview.com
- 6The company expects 200‑250 basis points of adjusted margin expansion in FY27. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.